Baclofen Matrix Tablet Floating Mechanism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Baclofen, a Class III BCS molecule, faces challenges with low oral bioavailability due to its hydrophilicity and poor permeability, leading to limited absorption in the gastrointestinal tract, which restricts therapeutic efficacy and requires frequent dosing, and existing gastroretentive formulations often fail to maintain gastric residence and ensure controlled release.
Innovation Solution
A matrix tablet formulation containing baclofen, a gas-generating agent, and a superdisintegrant, which quickly floats in gastric fluid, ensuring prolonged gastric residence and controlled release, enhancing absorption in the upper gastrointestinal tract.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If baclofen is administered orally at usual therapeutic doses, then good oral bioavailability is achieved, but frequent dosing is required due to limited absorption window
Solution Approach 1:
The patent applies preliminary action by pre-positioning the baclofen formulation in the stomach where it will float and release the drug over time, ensuring the drug is available at the absorption window (duodenum) when it passes through, thereby extending the absorption window and reducing dosing frequency while maintaining bioavailability
2Duration of action of moving object
If gastroretentive formulations are used to prolong gastric residence, then absorption time is extended, but existing formulations fail to maintain gastric residence and ensure controlled release
Solution Approach 1:
The patent applies the anti-weight principle by incorporating a gas-generating agent that produces gas bubbles, creating buoyancy force that counteracts gravity and gastric emptying forces, allowing the formulation to float on gastric contents and maintain gastric residence for extended periods while ensuring controlled release through the matrix structure
Solution Approach 2:
The patent applies composite materials by combining baclofen with a matrix-forming polymer (such as HPMC), gas-generating agents (such as sodium bicarbonate and citric acid), and superdisintegrants, creating a composite floating matrix tablet that simultaneously achieves gastric retention, controlled release, and sustained drug delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves improved flotation and prolonged gastric residence, allowing for sustained release of baclofen, thereby increasing bioavailability and reducing dosing frequency, making it suitable for once or twice daily administration.
Implementation Method 1
a gas-generating agent, which generates gas bubbles that cause the tablet to float rapidly on gastric contents
Implementation Method 2
a superdisintegrant, which causes the tablet to disintegrate and swell upon contact with gastric fluid
Implementation Method 3
The matrix structure controls the release rate of baclofen, allowing sustained release over an extended period
Data Source
AI summary
The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.